Application of a modelling system in the formulation of extended release hydrophilic matrices

Pharmaceutical Technology Europe

Volumn 18, Issue 7, 2006, Pages 20-26

  Levina, Marina ^a   Gothoskar, Abhijit ^b   Rajabi Siahboomi, Ali R ^a  

^a Colorcon ^*  (United States)

^b NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE DIBASIC; CHLORPHENIRAMINE MALEATE; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; LACTOSE; MACROGOL; METFORMIN; MICROCRYSTALLINE CELLULOSE; NIFEDIPINE; STARCH; THEOPHYLLINE;

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DECISION THEORY; DRUG DELIVERY SYSTEM; DRUG GRANULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EXTENDED DRUG RELEASE; HYDROPHILICITY; LOW DRUG DOSE; MATHEMATICAL MODEL; PROCESS OPTIMIZATION; RELIABILITY; STANDARDIZATION; TABLET COMPRESSION; TABLET FORMULATION; TABLET MANUFACTURE; TABLET MATRIX; VALIDATION STUDY;

EID: 33745906207     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. P. Colombo et al., Pharm. Sci. Tech. Today, 3(6), 198-204 (2000).
2. IMS data, 2002.
3. C.L. Li et al., J. Pharm. Pharmacol. 57(5), 533-546 (2005).
4. M.A. Longer and J.R. Robinson, Sustained-release drug delivery systems. in A.R. Gennaro (Ed.), Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing, PA, USA, 1990) pp 1676-1693.
5. A.R. Rajabi-Siahboomi and M.P Jorda, Eur. Pharm. Rev. 5(4) (2000) 21-23.
6. M.V. Velasco et al., J. Contr. Rel. 57(1), 75-85 (1999).
7. J. Siepmann and N.A. Peppas, Adv. Drug Deliv. Rev. 48(2-3), 139-157 (2001).
8. C.F. Rodrigues et al. Hydrophilic cellulose derivatives as drug delivery carriers: Influence of substitution type on the properties of compressed matrix tablets, in D.L. Wise (Ed.), Handbook of Pharmaceutical Controlled Release Technology, (Marcel Dekker, New York, NY, USA, 2000) pp 1-30.
9. H. Lapidus and N.G. Lordi, J. Pharm. Sci. 57(8), 1292-1301 (1968):
10. J.L. Ford, M.H. Rubinstein and J.E. Hogan, Int. J. Pharm. 24(2-3), 327-338 (1985).
11. J.L Ford et al., Int. J. Pharm. 40(3), 223-234 (1987).
12. R. Bettini et al., Eur. J. Pharm. Sci. 2(3), 213-219 (1994).
13. M.E. Campos-Aldrete and L. Vallafuerte-Robles, Eur. J. Pharm. Biopharm. 43(2),173-178 (1997).
14. K. Parfitt (Ed.), Martindale: The complete drug reference, (Pharmaceutical Press, London, UK, 1999) pp 45, 320, 330, 405, 765.
15. FDA Federal Register, Volume 60, No. 230, pp 61642 (1995). (5600 Fishers Lane, Rockville, MA 20857, USA).
16. J.W. Moore and H.H. Flanner, Pharm. Technol. 20(6), 64-74 (1996).
17. B. Abrahamsson, K. Roos and J. Sjogren, Drug Dev. Ind. Pharm. 25(6), 765-771 (1999).
18. F. Palmer, M. Levina and A. Rajabi-Siahboomi, Investigation of a Directly Compressible Metformin HCl 500 mg Extended Release Formulation Based on Hypromellose (CRS Annual Meeting, Miami, FL, USA, June 2005).
19. A. Gothoskar et al., Colorcon Technical Literature, 2006.
20. Chinese State Drug Specification WS1-(X-055)-2004Z.
21. United States Pharmacopeia 27, United States Pharmacopeial Convention, Inc., (12601 Twinbrook Parkway, Rockville, ML, 20852-1790, USA) 2004, pp 1323.